Ilsung IS일성아이에스
003120 · KOSPI · ₩003120 · 일성아이에스
- Market cap
- ₩287B
- Enterprise value
- ₩75B
- P/E
- 52.2×
- P/B
- 0.8×
- Dividend yield
- 5.6%
- ROE
- 1.4%
- Net margin
- 8.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−26.3% from the high
₩17,120Today: ₩21,350 – ₩21,700₩29,300
Returns
- 1W−1.6%
- 1M−1.6%
- 3M+3.3%
- 6M−7.1%
- YTD−0.9%
- 1Y−8.5%
- Volume today
- 1,757
- 0.3× the 20-day average
- Traded today
- ₩38M
- Listed shares
- 13,300,000
- EPS (12 months)
- ₩414
- Earnings yield 1.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.1% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Ilsung IS stock overview
Ilsung IS (일성아이에스, KRX: 003120) is listed on KOSPI, in the Biotech & Pharma sector. Ilsung Pharmaceuticals (renamed Ilsung IS, formerly Ilsung Pharm) is a Korean pharmaceutical company that researches, manufactures and sells specialized prescription medicines for the medical field, produced through technology partnerships with leading global pharmaceutical companies. Its shares closed at ₩21,600 on Oct 27, 2026, up 0.93% on the day, giving it a market value of ₩287B.
Key facts
- Market cap
- ₩287B
- Sector
- Biotech & Pharma
- Latest price change
- +0.93%
- As of
- Oct 27, 2026
- Main business
- Ilsung Pharmaceuticals (renamed Ilsung IS, formerly Ilsung Pharm) is a Korean pharmaceutical company that researches, manufactures and sells specialized prescription medicines for the medical field, produced through technology partnerships with leading global pharmaceutical companies.
Quick answers about Ilsung IS
- What does Ilsung IS do?
- Ilsung Pharmaceuticals (renamed Ilsung IS, formerly Ilsung Pharm) is a Korean pharmaceutical company that researches, manufactures and sells specialized prescription medicines for the medical field, produced through technology partnerships with leading global pharmaceutical companies. It focuses on antibiotics, producing penicillin-based antibiotics in collaboration with GlaxoSmithKline (GSK), including its flagship product Augmentin, and also sells a range of other drugs such as bone disease treatments, anesthetics, and contrast agents. Its products are sold domestically and exported, with its main operations at a factory in Ansan, South Korea, and its sales are mainly in the domestic market.
- What is the market cap of Ilsung IS?
- The market capitalisation of Ilsung IS was ₩287B at the close on Oct 27, 2026.
- Who are the largest shareholders of Ilsung IS?
- According to the latest official filings, the largest reported holders are Yoon Seok-geun (33.51%, as of Jul 23, 2026); National Pension Service (0.44%, as of Dec 31, 2025).
- When is the next earnings report from Ilsung IS?
- Korean companies rarely announce results dates in advance. Based on when Ilsung IS filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Ilsung IS?
- Yes. The National Pension Service held 0.44% of Ilsung IS shares as of Dec 31, 2025.
Company profile
Ilsung Pharmaceuticals (renamed Ilsung IS, formerly Ilsung Pharm) is a Korean pharmaceutical company that researches, manufactures and sells specialized prescription medicines for the medical field, produced through technology partnerships with leading global pharmaceutical companies. It focuses on antibiotics, producing penicillin-based antibiotics in collaboration with GlaxoSmithKline (GSK), including its flagship product Augmentin, and also sells a range of other drugs such as bone disease treatments, anesthetics, and contrast agents. Its products are sold domestically and exported, with its main operations at a factory in Ansan, South Korea, and its sales are mainly in the domestic market.
Written by AI from the company's latest annual report.
- Korean name
- 일성아이에스
- Sector
- Biotech & Pharma
- Themes
- —
- CEO
- 윤석근, 엄대식, 윤종호(각자대표)
- Founded
- Feb 1961
- Listed
- Jan 1985
- Listed shares
- 13,300,000
- Fiscal year ends
- Month 12
- Website
- www.ilsungis.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Trading haltSep 30, 2026
- Share cancellation decisionSep 30, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Change in largest shareholder's holdingsJul 23, 2026
- 5%+ holding reportJul 23, 2026
Titles in Korean until English translations are added.
Also known as: Ilsung IS / 일성아이에스 / 003120 / KRX:003120
Source: KRX statistical information